English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Studies suggest that RSV infection early in life is associated with the development of recurrent wheezing, yet, information on large population-based studies among US full-term healthy infants is incomplete. The objective of this study was to evaluate the risk of developing post-RSV recurrent wheezing/asthma during childhood among full-term infants in a US commercially insured population. Methods Retrospective, observational study used data from Truven MarketScan Commercial Claims and Encounters Database (January 1, 2000–December 31, 2016) to identify full-term infants with and without a RSV diagnosis in the first year of life (RSV and non-RSV cohorts respectively). Infants were excluded if they had any of the following: prematurity (<37 weeks’ gestation), low birth weight, small for gestational age, congenital heart or chronic lung disease, asthma or wheezing; or had received palivizumab. At least 2 years’ continuous follow-up post birth was required throughout the ≤5-year follow-up period. RSV/non-RSV infants were 1:1 matched for gender, region and health plan type. Cumulative incidence of recurrent wheezing or asthma was identified by ICD-9/10 codes, through 1, 2, 3 and 4 years (Y)’ post-index (1 year after birth) follow-up, and analyzed using conditional logistic regression. Results Matched RSV/non-RSV pairs totaled 38,494 (Y1), 25,603 (Y2), 17,429 (Y3), and 11,921 (Y4) for the years’ follow-up. Demographic characteristics, birth year and month were evenly represented between cohorts. Other infections during the perinatal period were more common in the RSV vs. the non-RSV cohort (5.4% vs. 3.2%; P < 0.0001), as were other respiratory conditions (5.8% vs. 2.6%; P < 0.0001), and antibiotic use (76.7% vs. 44.7%; P < 0.0001). Rates of influenza and pneumococcal vaccinations were comparable between cohorts. Cumulative incidence of recurrent wheezing or asthma in the RSV cohort was more than two-fold higher compared with the non-RSV cohort for each follow-up period (P < 0.001) (Figure 1). Conclusion Healthy, full-term, commercially insured children infected with RSV during the first year of life had from 2.2- to 3.6-fold increased risk of developing recurrent wheezing or asthma in the next 1–4 years. This reveals an important medical need for interventions targeting RSV infection in infants.Figure 1. Disclosures A. Mejias, Janssen: Grant Investigator and Scientific Advisor, Consulting fee and Research grant. Abbvie: CME talks, Speaker honorarium. B. Wu, Janssen Scientific Affairs, LLC: Employee and Shareholder, Salary. N. Tandon, Janssen Scientific Affairs: Employee and Shareholder, Salary and stocks. W. Chow, Janssen Scientific Affairs, LLC: Employee and Shareholder, Salary and stocks. N. Connolly, Janssen Scientific Affairs, LLC: Employee and Shareholder, Salary and Stocks. S. Lakhotia, Janssen Scientific Affairs, LLC: Research Contractor, Fee for service. E. Franco, Janssen Scientific Affairs, LLC: Employee and Shareholder, Salary and stocks. O. Ramilo, Janssen Scientific Affairs, LLC: Consultant, Consulting fee.

2352. Increased on Childhood Recurrent Wheezing and Asthma After Respiratory Syncytial Viral (RSV) Infection in Full-Term Infants